Product Identification

Product Name

9-(1,3-Dihydroxy-2-propoxymethyl)guanine

Synonyms

2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-h-purin-6-one
2-Amino-9-((1,4-dihydroxybutan-2-yloxy)methyl)-3H-purin-6(9H)-one
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-
9-(1,3-Dihydroxy-2-propoxymethyl)guanine
Cymevan
Hydroxyacyclovir

CAS

82410-32-0

Formula

C9H13N5O4

Molecular Weight

255.23

RTECS

MF8407000

RTECS Class

Drug; Mutagen

Merck

12,4374

Beilstein/Gmelin

3654487

Physical and Chemical Properties

Appearance

Crystals from methanol.

Solubility in water

Very soluble

Melting Point

250

pKa/pKb

9.15 (pKa)

Partition Coefficient

-2.07

Heat Of Vaporization

Usage

Medication.

First Aid Measures

Ingestion

Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.

Inhalation

If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.

Skin

Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.

Eyes

Manufacturer recommendations include caution in handling ganciclovir formulations (intravenous {alkaline ph 11} or oral) and to avoid direct contact with skin or mucous membranes.

Handling and Storage

Storage

Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

Hazards Identification

Inhalation

Pneumonia, dyspnea, and cough have been reported with ganciclovir.

Skin

Pruritus, rash, and sweating were the most frequent dermatologic complaints associated with intravenous or oral ganciclovir.

Ingestion

Vomiting, diarrhea, and anorexia have been reported in clinical trials. Upper gastrointestinal bleeding has occurred following ganciclovir therapy.

Exposure Controls/Personal Protection

Personal Protection

Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.

Respirators

Use NIOSH/MSHA approved respirator appropriate for exposure of concern.

Exposure Effects

Fever has occurred with ganciclovir therapy. neuropathy and paresthesia have occurred during clinical trials with immunocompromised patients. Seizures associated with ganciclovir use have also occurred. Ganciclovir is classified by the manufacturer as US FDA pregnancy category C.

Fire Fighting Measures

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Accidental Release Measures

Small spills/leaks

Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.

Stability and Reactivity

Stability

Exposure to temperatures exceeding 40 C should be avoided. When stored as directed, the sterile powder has an expiration date of 3 years following the date of manufacture.

Incompatibilities

Strong oxidizing agents.